Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03286452 · ClinicalTrials.gov registry record
The RESPOND Registry
A clinical trial of Venous Ulcer and Pressure Ulcer, sponsored by Organogenesis.
- Completed
- Registry status
- 310
- Enrollment target
- 15
- Study locations
NCT03286452: Completed study of Venous Ulcer and Pressure Ulcer, sponsored by Organogenesis.
NCT03286452 is a study of Venous Ulcer and Pressure Ulcer that has completed, run by Organogenesis. The registered enrollment target is 310 participants, above the 132-participant average among 11 other Venous Ulcer trials with a reported enrollment target (135% higher). The trial reports 15 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03286452, a study of Venous Ulcer and Pressure Ulcer, has completed, sponsored by Organogenesis.
- COMPLETED
- Registry status
- 310 participants
- Enrollment target
- 15
- Study locations
Study Summary
The RESPOND Registry is an observational study to assess the impact of PuraPly™ AM on the management of wounds in real world clinical settings; no experimental intervention is involved.
Primary Outcome
As measured from change in size from baseline
Conditions Studied
Interventions
- DEVICE PuraPly™ Antimicrobial Wound Matrix
Study Locations (15)
Louisiana
- Institute for Advanced Wound Healing; Northshore Specialty Hospital - Covington
- Wound Care Associates, LLC. - Hammond
- Opelousas General Hospital Wound Center - Opelousas
Florida
- Jupiter Medical Center - Jupiter
- West Gables Rehab Hospital - Miami
New Jersey
- CentraState Medical Center - Freehold
- Robert Wood Johnson Hamilton - Hamilton
Pennsylvania
- Sacred Heart Hospital - Allentown
- Harrisburg Foot and Ankle Center, Inc. - Harrisburg
Arizona
- Advanced Wound Care Center at Yavapai Regional Medical Center - Prescott Valley
Missouri
- Saint Louis Foot and Ankle - St Louis
New York
- Southampton Hospital - Southampton
North Carolina
- Wayne Memorial Hospital - Goldsboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2017-02-21 |
| Est. Completion | 2019-01-26 |
What the finished NCT03286452 record still lists
NCT03286452 is an observational study that tracks outcomes without assigning an intervention. The registered 310 participants enrollment target is mid-sized for trials with a published cap, above the 132-participant average among 11 other Venous Ulcer trials with a reported enrollment target (135% higher).
The record links to 8 conditions, with Venous Ulcer appearing as the primary indexed condition, and to 1 intervention - of which PuraPly™ Antimicrobial Wound Matrix is the first listed.
NCT03286452 lists 15 locations in 10 states (Louisiana, Florida, New Jersey).
Frequently Asked Questions
What is clinical trial NCT03286452 about?
NCT03286452 is a clinical study titled "The RESPOND Registry". The RESPOND Registry is an observational study to assess the impact of PuraPly™ AM on the management of wounds in real world clinical settings; no experimental intervention is involved.
What is the current status of trial NCT03286452?
This trial is currently completed. The enrollment target is 310 participants. The study started on 2017-02-21. Estimated completion is 2019-01-26.
What conditions does trial NCT03286452 study?
This clinical trial studies the following conditions: Venous Ulcer, Pressure Ulcer, Surgical Wounds, Trauma Wounds, Diabetic Ulcer.
What interventions are being tested in trial NCT03286452?
The interventions under investigation include: PuraPly™ Antimicrobial Wound Matrix (DEVICE).
Who is sponsoring clinical trial NCT03286452?
This trial is sponsored by Organogenesis, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03286452 being conducted?
This trial has 15 study locations across Arizona, Florida, Louisiana, Missouri, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Venous Ulcer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03286452's enrollment target sits among peer trials
310 3rd of 11 higher than 9 of 11 other Venous Ulcer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Venous Ulcer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tissue Repair Gel in Venous Leg Ulcers in AU/US
RECRUITING · Phase 3
-
Evaluating the Durability of Closure for Venous Leg Ulcers
RECRUITING
-
The GORE® VIABAHN® FORTEGRA Venous Stent Iliofemoral Study
RECRUITING · NA
-
A Multicenter, Prospective, Controlled Modified Multi-Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers.
RECRUITING · Phase 4
-
Tissue Repair Gel in Venous Leg Ulcers (US)
RECRUITING · Phase 3
-
The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03039439 · 310 participants
Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors
- NCT04178018 · 310 participants · NA
Transvaginal Ultrasound and Photoacoustic Imaging of Ovary
- NCT04878094 · 310 participants · Phase 3
A Study of Intra-operative Imaging in Women With Ovarian Cancer
- NCT05459233 · 310 participants · NA
Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI